MENU
IRD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Opus Genetics (IRD) Ownership - Who owns Opus Genetics?
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
58.27M
P/E Ratio
N/A
Total Cash
41.79M
Projected Growth
N/A
Total Debt
N/A
Revenue
13.65M
Risk (Beta)
0.74
Dividend Yield
N/A
Total Cash/Share
0.70
Total Debt/Equity
N/A
Revenue/Share
0.47 USD as % of share price
Fundamentals
IRD
Capitalization
58.3M
P/E Ratio
N/A
Risk (Beta)
0.74
Dividend Yield
N/A
Total Cash
41.8M
Total Cash/Share
0.70
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.47%
Revenue
13.7M
ROE
N/A
Book Value
5.07M
P/B Ratio
11.48
Cash Flow
N/A
Earnings
-2.1
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
5K
Current Ratio
1.98
Current Revenue Per Employee
242777.78
Dividends Per Share - Security
N/A
EBITDA
-57.23M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-117.23
Shares Held By Institutions
16.2M
Shares Outstanding - Current
59.7M
Total Liabilities
43.1M
Total Volume MTD
N/A
Value
-1
Gain YTD
-17.933
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics
Industry Biotechnology
Profile
Fundamentals
Details